In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
CRA expands its Antitrust Practice with addition of M&A specialist and litigation expert
“I am pleased to welcome Hitesh back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He specializes in antitrust...